Leerink Partners initiated coverage on Cencora with a new price target
$COR
Other Pharmaceuticals
Health Care
Leerink Partners initiated coverage of Cencora with a rating of Outperform and set a new price target of $261.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/3/2025 | $337.00 | Equal Weight → Overweight | Wells Fargo |
| 12/4/2024 | $280.00 | Outperform | Mizuho |
| 9/18/2024 | $275.00 → $245.00 | Buy → Neutral | BofA Securities |
| 2/26/2024 | $261.00 | Outperform | Leerink Partners |
| 1/3/2024 | $242.00 | Overweight | Barclays |
| 12/14/2023 | $213.00 | Equal Weight | Wells Fargo |
| 12/14/2021 | $162.00 → $170.00 | Buy → Neutral | Citigroup |
| 11/26/2021 | $136.00 → $170.00 | Sector Perform | RBC Capital |
11-K - Cencora, Inc. (0001140859) (Filer)
8-K - Cencora, Inc. (0001140859) (Filer)
SD - Cencora, Inc. (0001140859) (Filer)
Wells Fargo upgraded Cencora from Equal Weight to Overweight and set a new price target of $337.00
Mizuho resumed coverage of Cencora with a rating of Outperform and set a new price target of $280.00
BofA Securities downgraded Cencora from Buy to Neutral and set a new price target of $245.00 from $275.00 previously
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
3 - Cencora, Inc. (0001140859) (Issuer)
Cencora, Inc. (NYSE:COR) today announced that its Board of Directors has elected Lori J. Ryerkerk as a new independent director, effective June 1, 2025. "Ms. Ryerkerk's experience in complex, global supply chains will further strengthen the Board's expertise as we continue supporting the company's long-term growth. Her appointment reflects the Cencora Board's ongoing commitment to leaders who can help us contribute to driving stakeholder value," said Mark Durcan, Lead Independent Director. "Lori's experience as a public company CEO, leading a global specialties chemical company with extensive operations and logistics, will bring valuable insight as we execute against our strategy and bu
Revenue of $75.5 billion for the Second Quarter, a 10.3 percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $3.68 and Adjusted Diluted EPS of $4.42 Adjusted Diluted EPS Guidance Range Raised to $15.70 to $15.95 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described
Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 7, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call via
4 - Cencora, Inc. (0001140859) (Issuer)